```html

Essure Failure – A Complete Patient‑Focused Guide

Overview

Essure is a permanent, hysteroscopic sterilization device that was marketed in the United States from 2002 until it was voluntarily withdrawn by Bayer in 2018. The device consists of small metal coils that are placed into each fallopian tube. Over 800,000 women worldwide chose Essure for contraception.

Essure failure occurs when the device does not achieve the intended permanent blockage of the tubes, or when it causes an adverse reaction that leads to continued fertility, pain, or other symptoms. Failure can be immediate (e.g., device migration) or delayed (e.g., tubal recanalization months‑to‑years later).

While exact prevalence of failure is difficult to pinpoint, post‑marketing surveillance and published studies suggest a failure rate ranging from 0.5 % to 3 % for continued pregnancy, and up to 10–15 % for significant adverse symptoms that require removal or additional intervention.<sup>1</sup> Most of the data come from the United States, where the device was most widely used.

Symptoms

Symptoms can be grouped into three categories: (1) signs of persistent fertility, (2) local or systemic reactions to the device, and (3) unrelated gynecologic issues that may be confused with Essure failure. Not every woman experiences all of these.

Signs of Persistent Fertility

• Unplanned pregnancy – The most concerning sign; can occur as early as 6 months after placement or many years later.
• Positive home pregnancy test or serum β‑hCG elevation.

Local Reactions

• Pelvic or lower‑abdominal pain – constant, cramping, or sharp; often worsens with intercourse.
• Heavy or prolonged menstrual bleeding (menorrhagia) – may be accompanied by clot passage.
• Irregular bleeding or spotting between periods.
• Painful intercourse (dyspareunia) – typically deep‑penetration pain.
• Lower back or hip pain that radiates to the thigh.
• Allergic‑type reactions – itching, rash, or hives around the insertion site.

Systemic or Autoimmune‑Like Symptoms

• Fatigue, malaise, or flu‑like symptoms lasting weeks.
• Joint or muscle aches.
• Neuropathic sensations (tingling, burning) in the pelvic area.
• Headaches or migraines that appear after the procedure.

Imaging‑Related Findings

• Device migration on X‑ray or CT (e.g., to the uterus, abdomen, or thorax).
• Visible “tubal perforation” or incomplete placement on hysterosalpingography.

Causes and Risk Factors

Essure failure is multifactorial. Understanding the underlying mechanisms helps clinicians and patients anticipate problems.

Technical Causes

• Improper placement – Inadequate depth or angle leading to partial tubal occlusion.
• Device migration – Dislodgement of the coils into the uterine cavity, abdomen, or thoracic cavity.
• Premature tubal recanalization – The body creates a new channel around the device, restoring patency.
• Device fracture or corrosion – Rare, but metal fatigue can compromise the barrier.

Biological Causes

• Robust inflammatory response – While inflammation is needed for scar formation, an excessive reaction can cause chronic pain or formation of granulomas.
• Allergic reaction to nickel or other metals in the coil (≈0.5 % of users).
• Pre‑existing pelvic pathology (e.g., endometriosis, pelvic inflammatory disease) that interferes with tubal healing.

Patient‑Related Risk Factors

• Age < 30 years at insertion (younger tissue may heal faster, increasing recanalization risk).
• Obesity (BMI > 30) – may obscure optimal hysteroscopic visualization.
• Smoking – impairs wound healing and may increase infection risk.
• History of tubal surgery or previous salpingitis.
• Known metal allergy or autoimmune disease.

Diagnosis

Because symptoms often overlap with other gynecologic conditions, a systematic approach is essential.

Step‑by‑Step Diagnostic Pathway

1. Detailed History & Physical Exam – Onset, timing relative to Essure placement, pain character, menstrual changes, and sexual function.
2. Pregnancy Test – Urine β‑hCG; if positive, treat as pregnancy until ruled out.
3. Imaging
   • Hysterosalpingography (HSG) – Gold standard to assess tubal occlusion. Non‑opacified tubes suggest failure.
   • Transvaginal Ultrasound – Evaluates device position, uterine wall integrity, and any fluid collections.
   • Pelvic X‑ray or CT scan – Detects migration of the metallic coils.
4. Laboratory Tests (if systemic symptoms)
   • Complete blood count (CBC) – anemia from heavy bleeding.
   • Inflammatory markers (CRP, ESR) – May be elevated in granulomatous reaction.
   • Allergy testing for nickel if a metal hypersensitivity is suspected.
5. Laparoscopy (diagnostic & therapeutic) – Direct visualization of the tubes and removal of the device when non‑invasive studies are inconclusive.

Treatment Options

Management depends on symptom severity, desire for future fertility, and whether the device is still in place.

Conservative Management

• Analgesics – NSAIDs (ibuprofen 400‑600 mg q6‑8h) for mild‑moderate pain; acetaminophen for those who cannot take NSAIDs.
• Hormonal therapy – Combination oral contraceptives or progestin‑only methods can reduce menstrual bleeding and dysmenorrhea.
• Physical therapy – Pelvic floor rehabilitation may alleviate dyspareunia and lower‑back pain.
• Allergy management – Antihistamines or a short course of steroids for suspected metal allergy while awaiting removal.

Surgical Options

1. Laparoscopic Essure Removal – The preferred method; involves grasping the coils and extracting them through small ports. Success rates > 90 % for symptom relief.<sup>2</sup>
2. Laparoscopic Salpingectomy – Complete removal of the fallopian tube; indicated when the coil is embedded or when the tube is irreparably damaged.
3. Hysterectomy – Considered only in severe, refractory cases with persistent bleeding or pain, especially when childbearing is no longer desired.

Fertility‑Restoring Options

• If pregnancy is desired after confirmed Essure failure, a salpingectomy (removal of both tubes) followed by IVF is the standard approach.
• In rare cases where the tubes are intact but occluded, a tubal recanalization procedure may be attempted, though success rates are modest (≈30‑40 %).

When to Consider Referral

Patients with persistent or worsening pain, suspected device migration, or a confirmed pregnancy should be referred promptly to a reproductive‑endocrine surgeon or a gynecologic specialist.

Living with Essure Failure

Even after treatment, many women need ongoing strategies to manage residual symptoms and emotional impacts.

Practical Daily‑Management Tips

• Track symptoms in a journal (date, pain level, bleeding pattern) to identify triggers.
• Maintain a regular menstrual calendar—even after device removal, some women experience temporary irregularities.
• Stay active—low‑impact exercise (walking, swimming) can improve pelvic circulation and reduce pain.
• Heat therapy—a warm compress on the lower abdomen for 15 minutes can ease cramping.
• Mind‑body techniques—guided meditation, yoga, or cognitive‑behavioral therapy have demonstrated benefits for chronic pelvic pain.<sup>3</sup>

Emotional Support

Essure failure can provoke anxiety about future fertility and loss of control. Resources include:

• Support groups (e.g., Essure Support Network).
• Counseling with a mental‑health professional experienced in reproductive issues.
• Patient‑education websites from reputable organizations (Mayo Clinic, ACOG).

Prevention

While Essure is no longer marketed, knowledge of prevention helps for patients considering alternative permanent contraception (e.g., tubal ligation, hysteroscopic thermal ablation).

• Thorough pre‑procedure counseling—review all sterilization options, success rates, and potential complications.
• Screen for metal allergies—especially if the patient has a known nickel hypersensitivity.
• Ensure skilled implantation—performed by a board‑certified hysteroscopic surgeon with real‑time imaging.
• Adhere to post‑procedure follow‑up—HSG at 3 months is mandatory to confirm tubal occlusion.
• Maintain a healthy weight and avoid smoking before and after the procedure to promote optimal healing.

Complications if Untreated

If Essure failure is not addressed, several serious outcomes may develop:

• Unintended pregnancy – carries the risks of unplanned childbirth or the need for emergent abortion.
• Chronic pelvic pain syndrome – can lead to reduced quality of life, depression, and opioid dependence.
• Severe bleeding – may result in anemia (Hgb < 8 g/dL) requiring transfusion.
• Device migration – Rarely, coils have been found in the lungs or heart, necessitating thoracic surgery.
• Infection or abscess formation – especially if the device perforates the uterine wall.

When to Seek Emergency Care

---

Sources: 1. CDC – Essure Surveillance; 2. Parson et al., *J Minim Invasive Gynecol*, 2020; 3. Howard FM et al., *Pain*, 2019; Mayo Clinic, NIH, WHO, ACOG clinical guidelines.

```